Le Lézard
Classified in: Health
Subject: ATY

Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More


NEW YORK, July 30, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marinus investors who were adversely affected by alleged securities fraud between March 17, 2021 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=92696&wire=4

MRNS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

WHAT'S NEXT? If you suffered a loss in Marinus during the relevant time frame, you have until August 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP


These press releases may also interest you

at 03:00
MD Logistics LLC (hereinafter "MD"), a group company of NIPPON EXPRESS HOLDINGS, INC., is remaking the North Area of its existing warehouse in Plainfield in the U.S. state of Indiana into a dedicated pharmaceutical facility that will commence...

at 03:00
Compliancy Group strives to educate on all things healthcare compliance. Understanding how breaches occur and how to prevent them is a key component of compliance. Each month, Compliancy Group releases a breach report to spread awareness. Hacking...

at 03:00
Clarivate Plc a leading global provider of transformative intelligence, today announced the full agenda for the 2nd annual Summit LATAM, which will be held in Milan on October 7, 2024, ahead of the CPHI Milan conference. In partnership with the...

at 02:23
The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the following members: Henrik Kjaer Hansen, (Chairman, appointed by Novo Holdings A/S)Claus Berner...

at 02:20
Skanska has signed a contract with Harris Health System for the construction of a new healthcare building in Houston, Texas, USA. The contract is worth USD 54M, about SEK 570M, which will be included in the US order bookings for the third quarter of...

at 00:32
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a subsidiary of Merck & Co., Inc., Rahway, NJ, USA), to evaluate...



News published on and distributed by: